Onartuzumab
Names
[ CAS No. ]:
1133766-06-9
[ Name ]:
Onartuzumab
Biological Activity
[Description]:
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity[1].
[Related Catalog]:
[In Vitro]
Onartuzumab acts specifically by blocking HGF α-chain (but not β-chain) binding to MET[1]. Onartuzumab blocks HGF binding to human c-Met with an inhibitory concentration (IC)50 of 1.8 nM and inhibits the subsequent induction of c-Met auto-phosphorylation and cell proliferation in many cancer cell lines[2].
[In Vivo]
Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth[3]. Animal Model: Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells[3] Dosage: 30 mg/kg Administration: IP, twice a week for 2 mouth Result: Suppressed tumor growth, but did not affect the mean in vivo human HGF levels. Animal Model: U-87 MG tumor-bearing mice[3] Dosage: 30 mg/kg Administration: IP, once Result: Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression).
Chemical & Physical Properties
No Any Chemical & Physical Properties
Related Compounds
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.